The Beneficial Effects of Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain and Associated Mood Disorders Induced by Paclitaxel in Mice
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Mice with paclitaxel-induced chemotherapy peripheral neuropathy
- Dose used in the study
- Ultramicronised palmitoylethanolamide 30 mg/kg orally, one hour after the last paclitaxel injection, for 7 days; paclitaxel 8 mg/kg intraperitoneally every other day for a week; the antagonists AM281 (1 mg/kg) and GW6471 (2 mg/kg) given 30 minutes before palmitoylethanolamide in separate experiments
- Duration
- 7 days of palmitoylethanolamide treatment
- What was measured
- Pain hypersensitivity, spinal and hippocampal pro-inflammatory cytokines, and depressive- and anxiety-like behaviours; the role of PPAR-alpha and CB1 receptors using antagonists
What the authors reported
Ultramicronised palmitoylethanolamide reduced the development of hypersensitivity, which went with reduced spinal and hippocampal pro-inflammatory cytokines and reduced depressive- and anxiety-like behaviours. The PPAR-alpha antagonist GW6471 and the CB1 antagonist AM281 blocked these behavioural and antinociceptive effects.
Limits of this study
A mouse model of chemotherapy-induced neuropathy; it cannot show effect in people undergoing chemotherapy. The authors declare no conflict of interest.
Source
PubMed 36009049 · doi:10.3390/biom12081155
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.